Home > Press > BioForce Nanosciences Announces Confirmation of Its Nanoarray Patent
BioForce Nanosciences, Inc., a wholly-owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTCBB:BFNH), today announced that it has received notice from the U.S. Patent and Trademark Office (USPTO) that its "Protein Nanoarray" patent (US Pat. No. 6,573,369) has been upheld following a request for re-examination of the previously issued patent by a third party.
BioForce Nanosciences Announces Confirmation of Its Nanoarray Patent
AMES, IA | Posted on October 15th, 2007
BioForce currently commercializes ultramicro arrays that are created using its Nano eNabler(tm) system. These miniaturized diagnostic and discovery tests have features sizes in the one micrometer to twenty micrometer diameter range (a human hair is about 70 micrometers in diameter). The Protein Nanoarray patent covers arrays of proteins having feature sizes of less than one micron squared and containing one or more different protein species. This size scale represents the ultimate level of miniaturization for biological diagnostic and discovery tests.
"This patent has now undergone extraordinary analysis by the USPTO" explained Dr. Eric Henderson, BioForce's founder, CEO and co-inventor of the patent. "Our success in this reexamination gives us confidence that as we make progress toward commercial development of miniaturized diagnostic tests we will have the appropriate intellectual property protection. We have created prototype Protein Nanoarrays as described in this patent and are positioned to begin to commercialize them when the market is ready."
Curtis Mosher, BioForce's Vice President of R&D and co-inventor of the patent, stated, "We continue to make improvements in our Nano eNabler (tm) system that allow it to create extremely miniaturized diagnostics tests. With tests this small a single drop of blood, a tear, or a few cells from a cheek swab can be used for multiple diagnoses with minimal patient impact. This is a fundamental requirement for our long term business goal of patient empowerment and truly personalized medicine."
About BioForce Nanosciences, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization; patterning and cell adhesion; and printing proteins to guide neural cell growth. For more information, visit http://www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the Company's most recent filings with the Securities and Exchange Commission. The Company's actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.
For more information, please click here
RedChip Companies Inc.
1-800-REDCHIP (733-2447) ext 104
BioForce Nanosciences Holdings, Inc.
Greg Brown, CFO
515 233 8333 x118
Copyright © PrimeNewswire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014
Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014
Nanoparticle technology triples the production of biogas October 23rd, 2014
SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014
Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014
Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014
Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014
Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014
Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014
harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014